Skip to main content
Livermore
Livermore
ZHEN

BioAtla, Inc.

BCAB
Exchange
OTC
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001826892

No open-market purchases or sales by BioAtla, Inc. insiders were filed in the last 90 days; 21 institutions reported holding it in 13F filings for Q2 2026, worth $1.22M in total; no superinvestor holds it.

Holders of 5% or more of BCAB

Holders whose latest Schedule 13D or 13G filing reports 5% or more of BioAtla, Inc., largest stake first. The change is against the holder's previous filing.

Holders of 5% or more of BCAB
HolderLatest formStakeChangeFirst filedLatest filingFiling
Acorn Bioventures, L.P.13G/A8.30%4.84M shares–May 20, 20251 filingMay 20, 2025SEC
Highbridge Capital Management LLC13G/A7.70%4.84M shares−2.20 ppfrom 9.90%Feb 10, 20252 filingsApr 25, 2025SEC
Short Jay M PhD13G/A6.60%3.87M shares–Feb 14, 20223 filingsFeb 7, 2025SEC

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

30 Schedule 13D and 13G filings on BioAtla, Inc., newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on BCAB
Filed (ET)FilerFormStakeChangeEvent dateFiling
Oct 15, 20258:36 AM ETOpoka Investment Fund Co13G4.80%2.81M shares−1.30 ppfrom 6.10%Below 5%Jul 9, 2025SEC
May 20, 20252:26 PM ETAcorn Bioventures, L.P.and 4 others13G/A8.30%4.84M shares–May 15, 2025SEC
Apr 25, 20252:00 PM ETHighbridge Capital Management LLC13G/A7.70%4.84M shares−2.20 ppfrom 9.90%Mar 31, 2025SEC
Mar 18, 202512:17 PM ETOpoka Investment Fund Co13G6.10%3.55M sharesNewMar 6, 2025SEC
Feb 10, 20255:04 PM ETHighbridge Capital Management LLC13G9.90%7.35M sharesNewDec 31, 2024SEC
Feb 7, 20254:41 PM ETShort Jay M PhDand 1 other13G/A6.60%3.87M shares–Dec 31, 2024SEC
Jan 24, 20254:00 PM ETMillennium Management LLCand 2 others13G/A1.90%1.10M shares–Below 5%Dec 31, 2024SEC
Feb 27, 2023Short Jay M PhD13G/AOld format–––SEC
Feb 14, 2023Tang Capital Partners LP13G/AOld format–––SEC
Feb 14, 2023Cormorant Asset Management, LP13G/AOld format–––SEC
Feb 9, 2023Vanguard Group Inc13G/AOld format–––SEC
Feb 6, 2023Wellington Management Group LLP13G/AOld format–––SEC
Jan 9, 2023Soleus Private Equity Fund I, L.P.13D/AOld format–––SEC
Jun 10, 2022FMR LLC13G/AOld format–––SEC
Apr 28, 2022Tang Capital Partners LP13GOld format–New–SEC
Feb 14, 2022Short Jay M PhD13G/AOld format–––SEC
Feb 14, 2022Cormorant Asset Management, LP13G/AOld format–––SEC
Feb 11, 2022HBM Healthcare Investments (Cayman) Ltd.13G/AOld format–––SEC
Feb 11, 2022Pfizer Inc13G/AOld format–––SEC
Feb 9, 2022Vanguard Group Inc13GOld format–New–SEC
Feb 9, 2022FMR LLC13G/AOld format–––SEC
Feb 8, 2022Farallon Capital Management, L.L.C.13G/AOld format–––SEC
Feb 4, 2022Wellington Management Group LLP13GOld format–New–SEC
Sep 3, 2021Soleus Private Equity Fund I, L.P.13D/AOld format–––SEC
Jun 28, 2021Soleus Private Equity Fund I, L.P.13D/AOld format–––SEC
Apr 12, 2021FMR LLC13G/AOld format–––SEC
Feb 16, 2021Himalaya Parent LLC13GOld format–New–SEC
Feb 16, 2021Cormorant Asset Management, LP13G/AOld format–––SEC
Feb 16, 2021Pfizer Inc13GOld format–New–SEC
Feb 8, 2021FMR LLC13GOld format–New–SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell BioAtla, Inc. shares.

No Form 144 notices for BioAtla, Inc. are on file.